Literature DB >> 24900000

Comparison of the Intraperitoneal, Retroorbital and per Oral Routes for F-18 FDG Administration as Effective Alternatives to Intravenous Administration in Mouse Tumor Models Using Small Animal PET/CT Studies.

Chulhan Kim1, In Hye Kim2, Seo-Il Kim2, Young Sang Kim2, Se Hun Kang2, Seung Hwan Moon1, Tae-Sung Kim3, Seok-Ki Kim3.   

Abstract

PURPOSE: We compared alternative routes for (18)F-fluorodeoxyglucose (FDG) administration, such as the retroorbital (RO), intraperitoneal (IP) and per oral (PO) routes, with the intravenous (IV) route in normal tissues and tumors of mice.
MATERIALS AND METHODS: CRL-1642 (ATCC, Lewis lung carcinoma) cells were inoculated in female BALB/c-nu/nu mice 6 to 10 weeks old. When the tumor grew to about 9 mm in diameter, positron emission tomography (PET) scans were performed after FDG administration via the RO, IP, PO or IV route. Additional serial PET scans were performed using the RO, IV or IP route alternatively from 5 to 29 days after the tumor cell injection.
RESULTS: There was no significant difference in the FDG uptake in normal tissues at 60 min after FDG administration via RO, IP and IV routes. PO administration, however, showed delayed distribution and unwanted high gastrointestinal uptake. Tumoral uptake of FDG showed a similar temporal pattern and increased until 60 min after FDG administration in the RO, IP and IV injection groups. In the PO administration group, tumoral uptake was delayed and reduced. There was no statistical difference among the RO, IP and IV administration groups for additional serial PET scans.
CONCLUSION: RO administration is an effective alternative route to IV administration for mouse FDG PET scans using normal mice and tumor models. In addition, IP administration can be a practical alternative in the late phase, although the initial uptake is lower than those in the IV and RO groups.

Entities:  

Keywords:  Administration route; FDG; Intraperitoneal; Intravenous; Per oral; Retroorbital; Small animal PET

Year:  2011        PMID: 24900000      PMCID: PMC4043002          DOI: 10.1007/s13139-011-0087-7

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  13 in total

1.  The intestinal absorption of glucose.

Authors:  R M ATKINSON; B J PARSONS; D H SMYTH
Journal:  J Physiol       Date:  1957-03-11       Impact factor: 5.182

2.  In vivo tracking of stem cells for clinical trials in cardiovascular disease.

Authors:  John V Frangioni; Roger J Hajjar
Journal:  Circulation       Date:  2004-11-23       Impact factor: 29.690

3.  NanoPET imaging of [(18)F]fluoromisonidazole uptake in experimental mouse tumours.

Authors:  Matthias T Wyss; Michael Honer; Pius A Schubiger; Simon M Ametamey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-29       Impact factor: 9.236

4.  Optimizing experimental protocols for quantitative behavioral imaging with 18F-FDG in rodents.

Authors:  Wynne K Schiffer; Martine M Mirrione; Stephen L Dewey
Journal:  J Nucl Med       Date:  2007-02       Impact factor: 10.057

5.  Is enteral administration of fluorine-18-fluorodeoxyglucose (F-18 FDG) a palatable alternative to IV injection? Pre-clinical evaluation in normal rodents.

Authors:  T Higashi; S J Fisher; K Nakada; D J Romain; R L Wahl
Journal:  Nucl Med Biol       Date:  2002-04       Impact factor: 2.408

6.  Impact of animal handling on the results of 18F-FDG PET studies in mice.

Authors:  Barbara J Fueger; Johannes Czernin; Isabel Hildebrandt; Chris Tran; Benjamin S Halpern; David Stout; Michael E Phelps; Wolfgang A Weber
Journal:  J Nucl Med       Date:  2006-06       Impact factor: 10.057

7.  Radiolysis of 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) and the role of ethanol and radioactive concentration.

Authors:  Mark S Jacobson; Heather R Dankwart; Douglas W Mahoney
Journal:  Appl Radiat Isot       Date:  2009-01-21       Impact factor: 1.513

8.  Potential Biomarker of L-type Amino Acid Transporter 1 in Breast Cancer Progression.

Authors:  Zhongxing Liang; Heidi T Cho; Larry Williams; Aizhi Zhu; Ke Liang; Ke Huang; Hui Wu; Chunsu Jiang; Samuel Hong; Ronald Crowe; Mark M Goodman; Hyunsuk Shim
Journal:  Nucl Med Mol Imaging       Date:  2010-11-24

9.  Retro-orbital injection is an effective route for radiopharmaceutical administration in mice during small-animal PET studies.

Authors:  Cristina Nanni; Cinzia Pettinato; Valentina Ambrosini; Antonello Spinelli; Silvia Trespidi; Domenico Rubello; Adil Al-Nahhas; Roberto Franchi; Abass Alavi; Stefano Fanti
Journal:  Nucl Med Commun       Date:  2007-07       Impact factor: 1.690

10.  Euthanasia method for mice in rapid time-course pulmonary pharmacokinetic studies.

Authors:  Adam R Schoell; Bruce R Heyde; Dana E Weir; Po-Chang Chiang; Yiding Hu; David K Tung
Journal:  J Am Assoc Lab Anim Sci       Date:  2009-09       Impact factor: 1.232

View more
  10 in total

1.  No needle to fear: An approach to needle phobic patients.

Authors:  Lauren Hudswell; Joanne Pinson; Shakher Ramdave; Jason Bradley
Journal:  Asia Ocean J Nucl Med Biol       Date:  2020

Review 2.  Intraperitoneal Route of Drug Administration: Should it Be Used in Experimental Animal Studies?

Authors:  Abdullah Al Shoyaib; Sabrina Rahman Archie; Vardan T Karamyan
Journal:  Pharm Res       Date:  2019-12-23       Impact factor: 4.200

3.  Sublingual Atropine Administration as a Tool to Decrease Salivary Glands' PSMA-Ligand Uptake: A Preclinical Proof of Concept Study Using [68Ga]Ga-PSMA-11.

Authors:  Vincent Nail; Béatrice Louis; Anaïs Moyon; Adrien Chabert; Laure Balasse; Samantha Fernandez; Guillaume Hache; Philippe Garrigue; David Taïeb; Benjamin Guillet
Journal:  Pharmaceutics       Date:  2022-06-16       Impact factor: 6.525

4.  Intraperitoneal Glucose Transport to Micrometastasis: A Multimodal In Vivo Imaging Investigation in a Mouse Lymphoma Model.

Authors:  Zsombor Ritter; Katalin Zámbó; Xinkai Jia; Dávid Szöllősi; Dániel Dezső; Hussain Alizadeh; Ildikó Horváth; Nikolett Hegedűs; David Tuch; Kunal Vyas; Péter Balogh; Domokos Máthé; Erzsébet Schmidt
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

5.  A 24-hour temporal profile of in vivo brain and heart pet imaging reveals a nocturnal peak in brain 18F-fluorodeoxyglucose uptake.

Authors:  Daan R van der Veen; Jinping Shao; Sarah Chapman; W Matthew Leevy; Giles E Duffield
Journal:  PLoS One       Date:  2012-02-22       Impact factor: 3.240

6.  [(18)F]FDG-6-P as a novel in vivo tool for imaging staphylococcal infections.

Authors:  Bethany Mills; Ramla O Awais; Jeni Luckett; Dave Turton; Paul Williams; Alan C Perkins; Philip J Hill
Journal:  EJNMMI Res       Date:  2015-03-19       Impact factor: 3.138

7.  Cardiac Radionuclide Imaging in Rodents: A Review of Methods, Results, and Factors at Play.

Authors:  Francesco Cicone; David Viertl; Ana Maria Quintela Pousa; Thibaut Denoël; Silvano Gnesin; Francesco Scopinaro; Marie-Catherine Vozenin; John O Prior
Journal:  Front Med (Lausanne)       Date:  2017-03-29

8.  TJP1 Contributes to Tumor Progression through Supporting Cell-Cell Aggregation and Communicating with Tumor Microenvironment in Leiomyosarcoma.

Authors:  Eun-Young Lee; Minjeong Kim; Beom K Choi; Dae Hong Kim; Inho Choi; Hye Jin You
Journal:  Mol Cells       Date:  2021-11-30       Impact factor: 5.034

9.  Radionuclides transform chemotherapeutics into phototherapeutics for precise treatment of disseminated cancer.

Authors:  Nalinikanth Kotagiri; Matthew L Cooper; Michael Rettig; Christopher Egbulefu; Julie Prior; Grace Cui; Partha Karmakar; Mingzhou Zhou; Xiaoxia Yang; Gail Sudlow; Lynne Marsala; Chantiya Chanswangphuwana; Lan Lu; LeMoyne Habimana-Griffin; Monica Shokeen; Xinming Xu; Katherine Weilbaecher; Michael Tomasson; Gregory Lanza; John F DiPersio; Samuel Achilefu
Journal:  Nat Commun       Date:  2018-01-18       Impact factor: 14.919

10.  Concurrent treatment with ursolic acid and low-intensity treadmill exercise improves muscle atrophy and related outcomes in rats.

Authors:  Jae Cheol Kim; Yun Seok Kang; Eun Bi Noh; Baek Woon Seo; Dae Yun Seo; Gi Duck Park; Sang Hyun Kim
Journal:  Korean J Physiol Pharmacol       Date:  2018-06-25       Impact factor: 2.016

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.